China Fast-Tracks Pricing Approvals for New Medical Technologies

1. China's National Healthcare Security Administration (NHSA) is developing a fast-track pricing system for innovative medical technologies like surgical robots and brain-computer interfaces to reduce bureaucratic delays and boost developer returns [para. 1].

2. Billing categories and pricing standards by health-insurance authorities are essential for large-scale clinical use, but regulatory lags have hindered new product rollouts and financial planning for tech firms [para. 2].

3. NHSA announced a “pre-listing” pricing framework on April 20, offering pricing guidance during clinical trials for immediate billing post-approval [para. 3].

4. NHSA has issued 39 batches of guidelines, adding ~180 cutting-edge technologies including surgical robots, remote surgeries, brain-computer interfaces, artificial hearts, cochlear implants, artificial larynges, and digital pathology slices [para. 4].

5. Provincial-level pricing caused fragmentation, low standardization, and regional discrepancies; since 2024, NHSA guidelines aim to unify standards nationwide by 2025 [para. 5].

6. Advanced tech sector suffered without national billing criteria; Beijing Surgerii's executive noted it crippled domestic surgical robot makers [para. 6].

7. Professor Jiang Changsong emphasized that without billing, hospitals can't charge, blocking patient access; NHSA provides a “pass” for innovations [para. 7].

8. Brain-computer interfaces exemplify pre-approval codes: NHSA set trial guidelines a year before March approval, creating fees for invasive insertion/removal and noninvasive adaptation [para. 8].

9. Local prices: invasive insertions 6,000-7,000 yuan ($878-$1024), noninvasive ~1,000 yuan in Beijing, Hubei, Zhejiang; Beijing includes in Category A insurance at top hospitals, with nationwide wards being equipped [para. 9].

10. Header: Navigating costs and clinical value [para. 10].

11. NHSA's Jiang Bingzhen outlines pricing via four dimensions: tech maturity, clinical demand, industrial value, affordability; focuses on gaps, needs, maturity, labor value [para. 11].

12. Surgical robots tiered into navigation/partial/precise execution with coefficient-based pricing tied to base surgery; new remote surgery fee enables cross-province billing [para. 12].

13. NHSA uses listing to cut healthcare costs overall [para. 13].

14. For ventricular assist devices (artificial hearts), NHSA engaged five makers to reduce implant surgery costs from ~1M to 700,000 yuan [para. 14].

15. Proton therapy capped at 170,000-198,000 yuan in Shanghai, Zhejiang, Gansu, Anhui; Shanghai fast-tracked Ruijin Hospital's application [para. 15].